Japan· JP-1124022F1083
ロラゼパム
A lorazepam product containing ロラゼパム, registered in Japan by 沢井製薬, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Lorazepam is registered in 16 of 19 countries.
Countries holding a registration under ATC N05BA06 (lorazepam), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Lorazepam · ATC N05BA06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lorazepam costs, country by country.
Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.084 in France to $0.81 in Switzerland — a ×9.6 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lorazepam · price per daily dose (2.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.81
- ES Spain$0.16
- FR France$0.084
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ロラゼパム
- Manufacturer
- 沢井製薬
- Country
- Japan (JP)
- ATC code
- N05BA06
- ATC class
- Lorazepam
- Defined daily dose
- 2.5 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
413 interactions on record for lorazepam.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lorazepam · interactions on record
413 records
- 4 severe
- 70 moderate
- 22 minor
- 266 info
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
51 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05BA06
Lorazepam, as other registers publish it.
- CanadaAPO-LORAZEPAMAPOTEX INC
- CanadaAPO-LORAZEPAMAPOTEX INC
- CanadaAPO-LORAZEPAMAPOTEX INC
- United StatesAtivanHikma Pharmaceuticals USA Inc.
- United StatesAtivanHikma Pharmaceuticals USA Inc.
- United StatesAtivanBausch Health US LLC
- United StatesAtivanHikma Pharmaceuticals USA Inc.
- United StatesAtivanHikma Pharmaceuticals USA Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aa7aa129-e9dc-4d4b-b84d-6853c7146180 GET /v1/drugs/aa7aa129-e9dc-4d4b-b84d-6853c7146180?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．５ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1124022F1083",
"category": "内用薬",
"price_yen": 6.3,
"generic_name": "ロラゼパム",
"product_name_jp": null,
"therapeutic_class": "1124",
"transitional_expiry": null
}See everything about lorazepam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.